Journal of Cystic Fibrosis

Article	Citations
EPS10.06 Highly-effective CFTR modulation is associated with greater height and peak lung function in children with cystic fibrosis	250
EPS8.02 Evolving physiotherapy airway clearance technique (ACT) interventions during cystic fibrosis (CF) pregnancy in the variant specific therapy (VST) era	124
P172 Oscillometry: assessment of bronchial obstruction in children with cystic fibrosis	92
P078 Hyperacute response to cystic fibrosis transmembrane conductance regulator modulation	91
P402 Separation anxiety or a Kaftrio side effect? Implementation of cognitive behavioural therapy strategies with a young child with cystic fibrosis (CF): A clinical case study	90
P408 The halo effect in cystic fibrosis: when educated patients in turn educate their family carers	82
EPS10.07 Exacerbation characteristics and clinical outcomes in the elexacaftor/tezacaftor/ivacaftor era: same-same but different?	81
WS08.03 How does elexacaftor/tezacaftor/ivacaftor affect improvement in exercise capacity and body composition in adults with cystic fibrosis who have completed an exercise intervention?	79
P131 Effect of deprescribing from inhaled corticosteroids in people with cystic fibrosis: challenges & opportunities for a target trial emulation using the UK CF Registry	78
WS15.05 Improvements in structural lung disease in people with CF aged 12 and above on elexacaftor/tezacaftor/ivacaftor are sustained for up to two years	75
P296 Characteristics of carbohydrate metabolism disorders in children with cystic fibrosis in the Moscow region	73
P109 Safety of elexacaftor/tezacaftor/ivacaftor in patients 6 through 18 years with cystic fibrosis and at least one F508del allele: a retrospective Italian multicenter study	69
WS13.03 Anti-inflammatory effects of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis heterozygous for F508del	67
463: Clearance of colonized bacterial species in CF patients before and after elexacaftor/tezacaftor/ivacaftor	64
410 Multidisciplinary collaboration for transition readiness and planning	63
465: Intestinal function and transit relates to microbial dysbiosis in the CF gut	57
460: Prevalence of antimicrobial resistance mutations in Mycobacterium abscessus and associations with in vitro susceptibility testing	57
491 The Cystic Fibrosis Questionnaire–Revised and body image in adults in the era of elexacaftor-tezacaftor-ivacaftor	56
568: Quantifying regional pulmonary ventilation changes pre-/postivacaftor treatment in same subject using hyperpolarized 3He MRI	49
585: Development of a novel, cell-free, in vitro, high-throughput screening system for readthrough agents of nonsense mutations	48
620: Iterative screen identifies amphiphilic peptides that confer enhanced delivery of CRISPR-associated nucleases and adenine base editors to airway epithelia	48
524 Acid suppression therapy and associations with growth, gut microbiome, and early-onset lung disease in young children with cystic fibrosis	48
488: Bile acids, bacterial colonization, and lung inflammatory markers in infants with cystic fibrosis	47
508: Extracellular vesicles mediate bacteria–immune cell interactions in the respiratory tract	45
P209 Physical fitness and habitual physical activity in children with cystic fibrosis - do they improve with elexacaftor/tezacaftor/ivacaftor therapy?	44

P221 Tension-free vaginal tape – a 15-year review of effect on urinary incontinence in patients with cystic fibrosis	43
353: Electrolyte transport properties assay revealed less carbachol-stimulated short-circuit current in cultured human small airway epithelia	42
372 Cystic fibrosis does exist in India! A successful approach to education and improving awareness of cystic fibrosis of physicians and caregivers in India	41
558 Development of a gene editing strategy to treat cystic fibrosisassociated liver disease	41
140: Oh gee! Time tested OGTT annual screening improvement: A single-center experience	39
670: F508del and G542X sheep models exhibit a severe cystic fibrosis phenotype, and their tracheal epithelial cells respond to human therapeutics in vitro	39
148: Sustainably implementing impactful pre-visit planning using the electronic health record	39
P029 Antisense oligonucleotide-based drug development for cystic fibrosis patients carrying the 2789+5 G-to-A splicing mutation	38
P052 Introduction of an innovative “pill-swallowing school” in a cystic fibrosis paediatric population within a tertiary centre	37
249 Pharmacological rescue of CFTR premature termination codon mutations by novel small molecules	37
54 Recombinant pyocins as emerging therapies against respiratory infections with Pseudomonas aeruginosa	36
13 Extended-interval dosing of amikacin against Mycobacterium abscessus reduces efficacy in vitro	36
100 Vancomycin demonstrates activity against Mycobacterium abscessus in combination with guideline-recommended antibiotics under physiologically relevant stress conditions	36
11 Examining antibiotic regimen spectrum and clinical outcomes of pulmonary exacerbation treatment	36
43 Bacteriophages that kill Pseudomonas aeruginosa induce heterogenous cellular responses in the airway epithelium	36
647 Impact of newborn screening program with NextGen sequencing on direct patient care	35
624 Evaluating precision medicine tools in cystic fibrosis for racial and ethnic fairness	35
ePS2.02 Comparison of FEV on a remote spirometry device with hospital software in an adult cystic fibrosis cohort	34
WS10.03 Impact of triple CFTR modulator therapy on urinary incontinence symptoms in adults with cystic fibrosis	34
WS11.04 Confirmatory genetic testing for all cystic fibrosis screen positive newborns: a 12-year analysis	34
WS11.03 Repeated sweat testing in children with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID)	34
ePS4.03 Outcomes of COVID-19 in patients with cystic fibrosis in Wales, UK	33
ePS3.05 Induced levofloxacin resistance persists in evolved lineages of Pseudomonas aeruginosa isolates from people with cystic fibrosis after exposure to other inhaled antibiotics	33
P083 Decreased respiratory burst in circulating neutrophils after initiation of CFTR modulator therapy in cystic fibrosis patients with chronic lung infections	33
288 CFTR genetic variants and association with cancer	31
220: Using lean methodologies to influence oral glucose tolerance test completion in cystic fibrosis patients	31
P106 Upper airway disease in adults with cystic fibrosis: a cross-sectional study	31
P143 Bronchopulmonary infection/colonisation in Spanish cystic fibrosis patients: preliminary results of a multicentre study	30
5: Testosterone deficiency in men with cystic fibrosis: Understanding prevalence & association with clinical outcomes	30
314 A role for CFTR in pancreatitis	30
292 Mechanism of CFTR modulation on endothelial mechanosensitive channels	30
329 Intrinsic conformational dynamics required for CFTR gating cycle revealed by single-molecule Förster resonance energy transfer	29
314: The COVID-19 pandemic and trends in anxiety and depressive symptoms in adolescents with cystic fibrosis and their caregivers	28
WS03.03 Qualitative analyses of the experiences of people with end-stage cystic fibrosis lung disease receiving ELX/TEZ/IVA	28
306: Behavioral health resources and screening in military cystic fibrosis centers: A survey	28
348 Single-cell multi-omics profiling reveals novel regulatory networks of CFTR in the kidney	28
Treatment of intestinal and liver features in cystic fibrosis mice by the osmotic laxative polyethylene glycol	27
419 Role of macrophage cystic fibrosis transmembrane conductance regulator in lung inflammation	26
447 Mucociliary interactions and the vertical clearance assay 2.0	26
257 Rapid health decline in young cystic fibrosis transmembrane conductance regulatorG551D ferrets after discontinuation of cystic fibrosis transmembrane conductance regulator modulator	24
633 Extracellular vesicles as delivery vectors to enhance killing of bacteria and viruses by airway-recruited human neutrophils	24
59 Improving mycobacterial sputum culture collection in adult patients during the highly effective modulator therapy era	24
487 Evaluating use of doxycycline versus vancomycin for treatment of methicillin-resistant Staphylococcus aureus–associated acute pulmonary exacerbations in people with cystic fibrosis	24
132 Respiratory symptom changes during menstrual cycles in women with cystic fibrosis	24
341 Improving care for pregnant people with cystic fibrosis by increasing knowledge of obstetric providers	24
417 Resolvin D1 reduces cystic fibrosis lung disease and inflammation associated with mucus obstruction	23
P478 Multiple breath inert gas wash out in infants and toddlers with cystic fibrosis before and after initiating inhaled hypertonic saline	23
291 Development and validation of the Cystic Fibrosis Stress Questionnaire: A cystic fibrosis–specific measure of perceived stress	23
260 Cystic fibrosis transmembrane conductance regulator modulator–associated liver inflammation in pediatric cystic fibrosis	23
P227 Life threatening infection with a highly resistant Achromobacter xylosoxidans strain	23

145 Prescription of elexacaftor/tezacaftor/ ivacaftor in lung transplant recipients with cystic fibrosis	23
P024 Analysis of the effect of cytochrome P450 genes polymorphism on the efficacy and safety of CFTR modulator therapy in cystic fibrosis	23
Decline in HbA1c during the first year of elexacaftor/tezacaftor/ivacaftor treatment in the Danish cystic fibrosis cohort	22
332 Vocational rehabilitation services for people with cystic fibrosis: Predictors of employment outcomes	22
Characteristics associated with cystic fibrosis-related pulmonary exacerbation treatment location	22
Impact of azithromycin on serum inflammatory markers in children with cystic fibrosis and new Pseudomonas	22
51 Outcomes after SARS-CoV-2 infection in Canadians with cystic fibrosis: Analyses using the Canadian Cystic Fibrosis Registry	22
Using heart rate data from wrist worn activity trackers to define thresholds for moderate to vigorous physical activity in children and young people with cystic fibrosis	21
Vitamin D supplementation in patients with cystic fibrosis: A systematic review and meta-analysis	21
P104 CF-AMR Syndicate Collaborative Discovery Programme to accelerate the development of antimicrobials to treat lung infections in cystic fibrosis	20
European survey of newborn bloodspot screening for CF: opportunity to address challenges and improve performance	20
Evidence for secondary ciliary dyskinesia in patients with cystic fibrosis	20
P081 Elezacaftor/tezacaftor/ivacaftor therapy and quality of life in children and their caregivers	20
“Mind the gap”- will we ever see equal median predicted survival for males and females in cystic fibrosis?	20
Serological biomarkers for the diagnosis of Mycobacterium abscessus infections in cystic fibrosis patients	20
P379 TIDES 2.0: prevalence and longitudinal course of depression, anxiety, and behaviour problems in children with cystic fibrosis (CF) under 12 years of age	20
P352 Effect of ACE, ACTN3, PPARA, PPARGC1A gene polymorphisms on nutritional status in patients with cystic fibrosis in the Russian Federation	20
Improved early growth in Danish children with cystic fibrosis from 2000-2022	20
P249 Aspergillus fumigatus prevalence in Georgian paediatric cystic fibrosis patients	19
WS10.02Proteomic analysis of nasal lavage fluid and sputum samples in people with cystic fibrosis during 24 months of treatment with elexecaftor/tezacaftor/ivacaftor - The RECOVER study	19
P278 Trends in paediatric bone mineral density 2016-2024 – a single centre study	19
WS14.01Primary nasal epithelial cells for personalized medicine in non-eligible cystic fibrosis patients	19
P159 Long COVID in people with cystic fibrosis: a prospective observational study within the Italian Cystic Fibrosis Society	19
P341 Body composition and handgrip strength among children and adolescents with cystic fibrosis: correlation with anthropometric parameters and disease severity	19
P118 Community engagement and involvement in clinical trials and beyond…	19
P223 The role of horizontal Gene transfer in the development of resistance in Achromobacter ruhlandii	19
P174 A retrospective review of lung ultrasound in guiding physiotherapy input for people with cystic fibrosis in an in-patient setting	19
Sexual and reproductive health experiences and care of adult women with cystic fibrosis	18
P418 Recalibrating “a whole new life”: exploring the impact of elexacaftor/tezacaftor/ivacaftor on self-concept for adults with cystic fibrosis	18
P033 The impact of newborn bloodspot screening program modification in 2023 on the time of diagnosis in cystic fibrosis patients and follow-up care	18
Autoimmunity in people with cystic fibrosis	18
P308 Effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycaemic control in children with cystic fibrosis: a promising trend towards improved glucose regulation	18
Neurovascular complications post bronchial artery embolisation in patients with cystic fibrosis. A 7-year single centre retrospective review	18
P046 Investigating the safety of elexacaftor/tezacaftor/ivacaftor exposure during early development	18
P421 Accessing impact of elexacaftor/tezacaftor/ivacaftor therapy on antidepressant usage in an adult cystic fibrosis population	18
P282 Implementing routine assessment of gastrointestinal outcome measures in the cystic fibrosis clinic	17
Restoring airway epithelial homeostasis in Cystic Fibrosis	17
WS06.03 A real-world evaluation of remote monitoring in cystic fibrosis care: a mixed-methods multicentre observational study	17
Risk factors for cystic fibrosis arthropathy: Data from the German cystic fibrosis registry	17
P295 The results of colorectal cancer screening in patients with cystic fibrosis in Wales	17
WS19.01 Non-adherence in the twilight zone: the complexity of complex medications	17
Preclinical atherosclerosis in cystic fibrosis: Two distinct presentations are related to pancreatic status	17
P382 Cystic fibrosis and disordered eating behaviour: a collaborative approach to improve care	16
WS13.01 The cystic fibrosis Home Sputum-Induction Trial (CF-HomeSpIT - ISRCTN86523335) to evaluate home sputum-induction and early morning saliva sampling in children with cystic fibrosis	16
P007 Experience of using intestinal current measurement (ICM) in Russia	16
P219 Otorhinolaryngologic, audiological and genetic findings in children with cystic fibrosis: a tertiary care experience	16
P243 The effect of hypoxic conditions on Burkholderia cenocepacia clinical isolates from individuals with cystic fibrosis	16
P418 Patient satisfaction and clinical effectiveness of using the I-neb in children with cystic fibrosis (CF) in Wales	16
EPS5.08 Elexacaftor/tezacaftor/ ivacaftor reduces need for pancreatic enzymes, enteral feeding and omeprazole use without causing excessive weight gain: a 2-year observational study	16
P169 Vitamin absorption after the introduction of elexacaftor/tezacaftor/ivacaftor in children and adolescents diagnosed with cystic fibrosis	16
P104 The dynamics of health of children with cystic fibrosis in Russian Federation according to the registry data during last 10 years	16
P360 Mental health in cystic fibrosis patients: predictive factors and psychopathology	16
P387 Reviews and outcomes from a new pregnancy support service at a large cystic fibrosis centre	16
P134 Evaluation of multidisciplinary ambulatory care cost among children with cystic fibrosis: a comparative study between cystic fibrosis centers in Ireland and the United States	16
P017 The role of the VDR gene in the formation of clinical manifestations and complications in cystic fibrosis	16
260 RCT2100 rescue of cystic fibrosis (CF) transmembrane conductance regulator function in CF human bronchial epithelial cells and mucociliary clearance in CF ferrets	15
27 Standing up to the “bully”: Staphylococcus aureus can sustain long-term infection in the presence of Pseudomonas aeruginosa and may outcompete in the cystic fibrosis airway	15
39 Using mouse models to understand the critical roles of granulocyte macrophage colony stimulating factor and macrophages for control of pulmonary Mycobacterium abscessus infection	15
209 Inositol-requiring enzyme 1β is a therapeutic target for cystic fibrosis airway muco-obstructive disease	15
679 Effect of hybrid closed loop insulin delivery on glycemic control in adolescents and adults with cystic fibrosis-related diabetes	15
365 Differential effects of (S)- and (R)-vanzacaftor on BKCa potentiation and CFTR correction	15
490 What are the experiences of cystic fibrosis clinical nurse specialists? Are systemic practice ideas unknowingly incorporated when working with children and families?	15
Theranostics vs theratyping or theranostics plus theratyping?	15
235 Differential regulation of immune function by highly effective CFTR modulators in THP-1-derived macrophages	15
808 Implementation of physical therapy and exercise education in annual cystic fibrosis clinic	15
99 Development and validation of a deep neural network to predict antimicrobial resistance in people with cystic fibrosis using routinely collected electronic healthcare record data	15
304 Assessing a novel dual-endonuclease system in restoring CFTR expression in cystic fibrosis humanized mouse and human airway models	15
564 “How do you live the best life you can with this pain?” A qualitative study of the challenges of living with CF and pain in the modulator era	15
184 Bioengineered three-dimensional cystic fibrosis lung airway model for drug testing	15
526 Non-surgical management of urinary incontinence in women with cystic fibrosis	14
586 Description of a novel therapeutic support group for siblings of children with cystic fibrosis: Siblings Supporting Others and Achieving Resilience	14
462 Cystic fibrosis mental health and wellness questionnaire—factors and properties	14
160 LUNAR-CFTR mRNA improves mucociliary clearance in cystic fibrosis ferrets	14
Structure basis of CFTR folding, function and pharmacology	14
773 A quality improvement project to improve the evaluation of low bone density in people with cystic fibrosis	14
558 Challenges faced by parents of children with cystic fibrosis in Ireland: The Irish Comparative Outcome Study of Cystic Fibrosis	14
480 Weight stigma among healthcare professionals treating CF in North America	14
Clinical efficacy of CFTR modulator therapy in people with cystic fibrosis carrying the I1234V mutation	14
166 Single-cell and bulk transcriptomes in the nasal epithelium of people with cystic fibrosis demonstrate cell-type compositional heterogeneity	14
320 Gain-of-function CFTR mutation improves function of W1282X CFTR	14

529 Are adults with cystic fibrosis choosing to continue with airway clearance therapy in the era of highly effective gene modulator therapy?	14
644 Timely initiation of pancreatic enzyme replacement therapy for surgical cystic fibrosis infants in the neonatal intensive care unit	14
When CFSPID becomes CF	14
84 Plasmids acquired during the course of cystic fibrosis infections cause extreme antibiotic resistance in Pseudomonas aeruginosa	14
542 Improving nutrition outcomes through implementation of a standardized nutrition treatment algorithm in infants with cystic fibrosis younger than 2	13
1 High Ca++ does not hinder cyclic diguanosine monophosphate–mediated control of the Pseudomonas aeruginosa biofilm life cycle	13
521: Dual targeting of host and fungal sphingosine-1-phosphate lyase as antifungal strategy in cystic fibrosis	13
569 Symptom changes throughout the menstrual cycle in women with cystic fibrosis	13
142 Elexacaftor-tezacaftor-ivacaftor and spirometry-controlled chest CT scores in children with cystic fibrosis aged 6 to 11	13
536 Effect of elexacaftor-tezacaftor-ivacaftor on nutritional status and glucose metabolism in children and adolescents with cystic fibrosis	13
643: A novel splice modulator compound corrects splicing defect caused by c.2988G >A variant in CFTR	13
37 Antibiotics to treat common cystic fibrosis airway pathogens influence susceptibility to Mycobacterium abscessus lung infection	13
523: Prevalence of Staphylococcus aureus in cystic fibrosis with reduced susceptibility to beta-lactam antibiotics at high inoculum	13
72 Investigating polymicrobial interactions involving Streptococcus in the cystic fibrosis airway	13
634: Identification of binding sites for ivacaftor on CFTR	13
552 Using the TriNetX database to describe the prevalence of VTE and gastrointestinal disease in children with cystic fibrosis	13
49 Bacterial siderophores drive cefiderocol resistance and crossprotection	13
476 “Thin and watery”: online discussions of sexual and reproductive health by men with cystic fibrosis	13
102 Clinical Pseudomonas aeruginosa isolates from cystic fibrosis sinusitis prevent flagellin-mediated immune recognition	13
626: VX-770 does not efficiently activate human CFTR in digitonin	13
395 Health equities assessment—Southern California Research Consortium	12
P001 Cystic fibrosis newborn screening (CF-NBS) start-up in Flanders (Belgium): report of first evaluation after 3 years	12
P030 Effect of CFTR modulators on lung function, body mass index, and Pseudomonas aeruginosa status in adolescents with cystic fibrosis - one-year follow-up	12
414 National patterns of CF RISE uptake and engagement: a multidimensional approach to increase transition program utilization	12
363: Losartan increases the efficacy of CFTR modulators to reverse inflammation-related mucociliary dysfunction	12
375: Exposure to healthy or cystic fibrosis sputum alters ion transport across human bronchial epithelial cells	12
398 Reducing costs for testing related to positive cystic fibrosis newborn screens	12
P024 Patient-derived organoids as a model for treatment diagnosis in cystic fibrosis – combinatory treatment with read-through agent, correctors and potentiator on rare mutations	12
649 Decreasing waiting room times in a cystic fibrosis clinic: a quality improvement project	12
385: Generation of FOXi1-KO ferrets using CRISPR/Cas9 gene editing to inform pulmonary ionocyte biology	12
412 Increasing the number of people with cystic fibrosis seen in outpatient clinic quarterly	12
P249 Awareness of the potential benefits of occupational therapy in a cystic fibrosis multidisciplinary team	12
482 Changing the conversation: exploring the influence of participation in a withdrawal study on clinical communication	12
401 Black and Hispanic people with cystic fibrosis (PwCF) and PwCF with high lung function are less likely to be prescribed elexacaftortezacaftor-ivacaftor despite having an eligible genotype	12
151: Time to prescription of Trikafta for remote and local dwelling patients with cystic fibrosis	12
434: Interspecies signaling during cystic fibrosis airway infection: How cAMP and c-di-GMP direct Pseudomonas aeruginosa chemotaxis toward Staphylococcus aureus	12
461: Unraveling the role of IL-17 receptor C during development of airway chronic infections by Pseudomonas aeruginosa	12
374: Rheological comparison of solubility and gel permanence between airway mucin solutions and mucus systems	12
239 Organoid-guided synergistic treatment of minimal function CFTR mutations with CFTR modulators, roflumilast and simvastatin: A personalized approach	11
P071 The characterisation of a patient cohort that had home spirometry devices and opted into sharing their data with the US Cystic Fibrosis Foundation	11
333 Assessing CFTR modulator response for an individual with H609R/ 2184insA using different in-vitro model systems	11
83: CF Global Care: Continuation of the collaboration between 2 CF centers; University of Michigan, USA, and Marmara University, Istanbul, Turkey, in the COVID-19 pandemic	11
53: Distinct early life growth trajectories in CF are associated with lung function at 6 years	11
ePS3.07 Exploring the therapeutic potential of iminosugars as antibacterial and antibiofilm agents in the treatment of cystic fibrosis lung disease infections	11
P046 The effectiveness of CFTR modulators in people with cystic fibrosis and rare mutations – a real-world study	11
ePS2.04 Is tele-physiotherapy as effective as home-visit-guided physiotherapy among children with cystic fibrosis?	11
60: The real-world effectiveness of U.S. CF newborn screening	11
WS20.03 What to hope for when there is no hope	11
161: Inter-visit reproducibility of free-breathing lung magnetic resonance imaging in cystic fibrosis	11
245 Generation of airway basal stem cells from induced pluripotent stem cell–derived airway progenitors: elucidation of signaling pathways responsible for basal cell maturation and proliferation	11
ePS4.08 COVID-19 vaccine uptake in adult people with cystic fibrosis	11
79: A patient satisfaction survey regarding the use of telemedicine for outpatient CF endocrinology and diabetes care during the COVID-19 pandemic	11
327 Data analysis for large-scale theratyping study of 656 CFTR variants	11
WS10.02 People with cystic fibrosis on elexacaftor/tezacaftor/ivacaftor therapy demonstrate improved physical activity levels and cardiovascular fitness	10
Contents	10
22: Unique challenges of treating women with cystic fibrosis–related diabetes in pregnancy	10
339 Diagnostic dilemmas in cystic fibrosis screen–positive infants with F191V and low sweat chloride	10
349 Intestinal epithelial-specific Cftr knockout induces fecal dysbiosis and bowel inflammation in mice consuming anti-obstructive dietary regimens	10
WS04.02 Clinical impact of pathogenic CFTR mutations in paediatric-onset pancreatitis (preliminary analysis from the APPLE study)	10
293: Perceptions and understanding of CFTR modulators	10
P462 Applicability of A-STEP performance test in patients diagnosed with cystic fibrosis in Turkish population	10
No patient left behind! Therapeutic options for cystic fibrosis patients living with lung transplantation	10
WS05.05 Proximity profiling of the CFTR interaction landscape in response to Orkambi	10
328: What COVID taught us—Collaboration in pursuit of expanded paid leave	10
WS04.05 What is the scope for colorectal cancer screening in cystic fibrosis? Ten years of experience at a UK cystic fibrosis centre	10
38: Real-world longitudinal trends in clinical outcomes in people with cystic fibrosis using lumacaftor/ivacaftor and tezacaftor/ivacaftor	10
P460 Assessing the exercise capacity of adolescents with cystic fibrosis in the post elexacaftor/tezacaftor/ivacaftor era, via cardiopulmonary exercise test	10
154 Inhibition of the intermediate (KCa3.1) and small (KCa2.3 and KCa2.2) conductance, Ca2+-activated K+ channels by CFTR correctors	10
P171 Improved diagnosis and treatment of distal intestinal obstruction syndrome (DIOS) with a simplified treatment routine	10
P208 A retrospective observational study of the effects of Kaftrio® on the current cohort of patients at Nottingham University Hospitals NUH trust	10
344 Unraveling the complexity of cystic fibrosis: genetic modifiers and their roles in cystic fibrosis pathogenesis	10
EPS2.06Exploring the diversity of nontuberculous mycobacteria in cystic fibrosis centers across the U.S.: Lessons from the prospective HALT study	9
P453 A study on patient and healthcare provider experiences with outpatient sexual and reproductive healthcare for adults with cystic fibrosis: insights from a single-center study	9
P163 The role of pharmacists in cystic fibrosis care: preliminary results from a systematic review	9
P345 Increasing prevalence of pancreatic sufficiency in a paediatric CF unit – are CFTR modulators the cause?	9
P373 Does visualising lung function and Body mass index (BMI) trends using the ‘My report’ section on the cystic fibrosis registry database help clinical decision making and improve the patient experi	9
P323 European practices in vitamin supplementation for cystic fibrosis since the introduction of CFTR modulators	9
P439 The role of the Research Play Specialist in CF Clinic, helping children and adolescents to develop coping strategies to overcome some of their anxieties in relation to blood sampling and beyond	9
P333 Scoping review protocol: Diet composition and quality in children with cystic fibrosis in the modulator era	9
EPS1.05Sleep quality and mental health in children with cystic fibrosis: the impact of elexacaftor/tezacaftor/ivacaftor therapy	9
P139 Chronic production of IL-23 activates a functional heterogeneity of IL-17F-producing cells, which untangle the immunological signature in young adult cystic fibrosis patients with early ABPA diag	9
P285 Assessing potential of FIB-4 index and transient elastography for use in an adult cystic fibrosis population	9
P205 Adult annual reviews at the West Midlands Adult cystic fibrosis Centre (WMACFC): a service improvement project	9
P274 Muddying the waters with menopause! How important is addressing the menopause in terms of cystic fibrosis care: Antibiotics or hormone replacement therapy?	9
WS07.01‘Silent' lung disease progression in people receiving elexacaftor/tezcaftor/ivacaftor (ETI) therapy revealed by Oxygen Enhanced-MRI (OE-MRI) and Multiple breath washout with Short extension (MB	9
EPS5.09Influencing factors of physical activity in youth with cystic fibrosis: a socio-ecological approach	9
WS09.01CFTR activity in nasal epithelia from subjects with different genotypes	9
EPS4.02Impact of ETI therapy on liver stiffness: a longitudinal study in children and adults	9
EPS6.07Correlation of responses in patient derived rectal organoids and clinical responses to modulators in people with CF homozygous for F508del-CFTR	9
P431 Factors related to higher level of physical activity in Swedish cystic fibrosis-patients – a registry-based cross sectional study	8
693 Machine learning analysis of continuous glucose monitoring after elexacaftor/tezacaftor/ivacaftor initiation in young children predicts dysglycemia better than an oral glucose tolerance test	8
P433 Association of physical activity with quadriceps force and functional performance in children with cystic fibrosis and healthy peers	8
P381 A five-day pilot randomised controlled trial of two mindfulness-based interventions for adults with cystic fibrosis	8
Long-term outcomes in people with CF lacking FEV1 response to elexacaftor/tezacaftor/ivacaftor therapy	8
Olfactory loss in people with cystic fibrosis: Community perceptions and impact	8